CN112638382B - 作为epac抑制剂的噻吩并[2，3-b]吡啶衍生物及其药物用途 - Google Patents

作为epac抑制剂的噻吩并[2，3-b]吡啶衍生物及其药物用途 Download PDF

Info

Publication number
CN112638382B
CN112638382B CN201980037932.4A CN201980037932A CN112638382B CN 112638382 B CN112638382 B CN 112638382B CN 201980037932 A CN201980037932 A CN 201980037932A CN 112638382 B CN112638382 B CN 112638382B
Authority
CN
China
Prior art keywords
epac
epac1
group
alkyl
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980037932.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN112638382A (zh
Inventor
J-P·布隆多
A·科吕西亚
M·劳德特
F·勒佐亚尔克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Paris Thackeray, University of
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Toulouse
Universita degli Studi di Roma La Sapienza
Original Assignee
Paris Thackeray, University of
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Toulouse III Paul Sabatier
Universita degli Studi di Roma La Sapienza
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paris Thackeray, University of, Institut National de la Sante et de la Recherche Medicale INSERM, Universite Toulouse III Paul Sabatier, Universita degli Studi di Roma La Sapienza filed Critical Paris Thackeray, University of
Publication of CN112638382A publication Critical patent/CN112638382A/zh
Application granted granted Critical
Publication of CN112638382B publication Critical patent/CN112638382B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN201980037932.4A 2018-06-06 2019-06-06 作为epac抑制剂的噻吩并[2，3-b]吡啶衍生物及其药物用途 Active CN112638382B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18305685 2018-06-06
EP18305685.2 2018-06-06
PCT/EP2019/064886 WO2019234197A1 (en) 2018-06-06 2019-06-06 Thieno[2,3-b]pyridine derivatives as epac inhibitors and their pharmaceutical uses

Publications (2)

Publication Number Publication Date
CN112638382A CN112638382A (zh) 2021-04-09
CN112638382B true CN112638382B (zh) 2024-10-18

Family

ID=62715982

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980037932.4A Active CN112638382B (zh) 2018-06-06 2019-06-06 作为epac抑制剂的噻吩并[2，3-b]吡啶衍生物及其药物用途

Country Status (6)

Country Link
US (1) US20210230179A1 (https=)
EP (1) EP3801511A1 (https=)
JP (1) JP7445609B2 (https=)
KR (1) KR20210057704A (https=)
CN (1) CN112638382B (https=)
WO (1) WO2019234197A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4072547A1 (en) * 2019-12-13 2022-10-19 Institut National De La Sante Et De La Recherche Medicale - Inserm Epac1 inhibitors for the treatment of idiopathic pulmonary fibrosis
WO2021250231A1 (en) * 2020-06-12 2021-12-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Thienopyridine derivatives for use in the treatment of coronavirus infection

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014089378A1 (en) * 2012-12-07 2014-06-12 Siga Technologies, Inc. Thienopyridine derivatives for the treatment and prevention of dengue virus infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60325051D1 (de) * 2002-06-06 2009-01-15 Boehringer Ingelheim Pharma SUBSTITUIERTE 3-AMINO-THIENO(2,3-b)PYRIDINE-2-AMIDE UND HERSTELLUNGSVERFAHREN SOWIE DEREN VERWENDUNG
AU2007275221A1 (en) * 2006-07-20 2008-01-24 Allen J. Borchardt Benzothiophene inhibitors of RHO kinase
US20110077250A1 (en) * 2009-06-26 2011-03-31 Ryder Sean Compounds for modulating rna binding proteins and uses therefor
US9751838B2 (en) 2012-10-02 2017-09-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Tetrahydroquinoline derivatives and their use as Epac inhibitors
AU2014342811B2 (en) 2013-10-15 2019-01-03 Board Of Regents Of The University Of Texas System Compositions and methods of modulating short-chain dehydrogenase activity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014089378A1 (en) * 2012-12-07 2014-06-12 Siga Technologies, Inc. Thienopyridine derivatives for the treatment and prevention of dengue virus infections

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CAS：340817-81-4.STN Registry Database.2001, *

Also Published As

Publication number Publication date
EP3801511A1 (en) 2021-04-14
JP2021527071A (ja) 2021-10-11
US20210230179A1 (en) 2021-07-29
CN112638382A (zh) 2021-04-09
KR20210057704A (ko) 2021-05-21
JP7445609B2 (ja) 2024-03-07
WO2019234197A1 (en) 2019-12-12

Similar Documents

Publication Publication Date Title
JP6660993B2 (ja) デオキシウリジントリホスファターゼ阻害剤
JP6513095B2 (ja) ヘテロ原子含有デオキシウリジントリホスファターゼ阻害剤
US8481553B2 (en) Antimetastatic compounds
HK1219432A1 (zh) 以嘧啶化合物爲有效成分的医药组合物
CN104814970A (zh) 抑制egfr导致的癌症中细胞增殖的方法
US20200270229A1 (en) Pharmaceutical composition for preventing or treating acute myeloid leukemia or metastatic breast cancer
ES2787599T3 (es) Inhibidores de leucemia inv(16)
US20170079972A1 (en) Novel ros1 inhibitor and its use
CN111053768A (zh) 用于治疗黑素瘤的药物组合
WO2017006283A1 (en) Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage
ES2958528T3 (es) Macrociclos sustituidos útiles como inhibidores de quinasas
US20180148437A1 (en) Novel Ezrin Inhibitors and Methods of Making and Using
EA019110B1 (ru) Замещенные хиназолиновые соединения
ES2930081T3 (es) Pirazolopirimidinas sustituidas útiles como inhibidores de quinasas
CN112638382B (zh) 作为epac抑制剂的噻吩并[2，3-b]吡啶衍生物及其药物用途
KR20100014480A (ko) Ｌｙｎ 키나제 활성제의 확인 방법
JP2023528945A (ja) Ｆｒｓ２－ｆｇｆｒ相互作用の小分子阻害剤、並びに医薬における、がんの予防及び治療における、その使用
US10093627B2 (en) Tetrahydroquinoline derivatives and their use as Epac inhibitors
US20210047300A1 (en) Hetero ring-fused phenyl compounds for inhibiting tnik and medical uses thereof
CN103044460A (zh) 3,5,7-三苯基-5H-噻唑并[3,2-a]嘧啶类衍生物及应用
WO2023105008A1 (en) Small-molecule inhibitors of the frs2-fgfr interaction
WO2024121437A1 (en) Small-molecule inhibitors of the frs2-fgfr interaction
TW201217341A (en) Receptor-type kinase modulator and methods of treating polycystic kidney disease

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant